Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England

Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women an...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Annabel A, Power, Linda, Westrop, Samantha, McOwat, Kelsey, Campbell, Helen, Simmons, Ruth, Ramsay, Mary E, Brown, Kevin, Ladhani, Shamez N, Amirthalingam, Gayatri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284043/
https://www.ncbi.nlm.nih.gov/pubmed/34269172
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.28.2100634
_version_ 1783723319181180928
author Powell, Annabel A
Power, Linda
Westrop, Samantha
McOwat, Kelsey
Campbell, Helen
Simmons, Ruth
Ramsay, Mary E
Brown, Kevin
Ladhani, Shamez N
Amirthalingam, Gayatri
author_facet Powell, Annabel A
Power, Linda
Westrop, Samantha
McOwat, Kelsey
Campbell, Helen
Simmons, Ruth
Ramsay, Mary E
Brown, Kevin
Ladhani, Shamez N
Amirthalingam, Gayatri
author_sort Powell, Annabel A
collection PubMed
description Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).
format Online
Article
Text
id pubmed-8284043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-82840432021-07-27 Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England Powell, Annabel A Power, Linda Westrop, Samantha McOwat, Kelsey Campbell, Helen Simmons, Ruth Ramsay, Mary E Brown, Kevin Ladhani, Shamez N Amirthalingam, Gayatri Euro Surveill Rapid Communication Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9). European Centre for Disease Prevention and Control (ECDC) 2021-07-15 /pmc/articles/PMC8284043/ /pubmed/34269172 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.28.2100634 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Powell, Annabel A
Power, Linda
Westrop, Samantha
McOwat, Kelsey
Campbell, Helen
Simmons, Ruth
Ramsay, Mary E
Brown, Kevin
Ladhani, Shamez N
Amirthalingam, Gayatri
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title_full Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title_fullStr Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title_full_unstemmed Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title_short Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
title_sort real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost covid-19 vaccination, march−june 2021, england
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284043/
https://www.ncbi.nlm.nih.gov/pubmed/34269172
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.28.2100634
work_keys_str_mv AT powellannabela realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT powerlinda realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT westropsamantha realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT mcowatkelsey realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT campbellhelen realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT simmonsruth realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT ramsaymarye realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT brownkevin realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT ladhanishamezn realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england
AT amirthalingamgayatri realworlddatashowsincreasedreactogenicityinadultsafterheterologouscomparedtohomologousprimeboostcovid19vaccinationmarchjune2021england

Ejemplares similares